Teva Pharmaceuticals USA, Inc. and MedinCell S.A. announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia. The application included Phase 3 data from two pivotal studies: TV46000-CNS-30072 (the RISE Study The Risperidone Subcutaneous Extended-Release Study) and TV46000-CNS-30078 (the SHINE Study A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia). These studies evaluated the efficacy and long-term safety and tolerability of TV-46000 as a treatment for patients with schizophrenia.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
16.22 EUR | -0.86% | +6.57% | +125.28% |
05-15 | Medincell: share price falls after disappointing clinical study | CF |
05-15 | Transcript : MedinCell S.A. - Special Call |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+125.28% | 516M | |
+40.73% | 739B | |
+31.66% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+14.70% | 240B | |
+9.45% | 210B | |
-4.95% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- MEDCL Stock
- News MedinCell S.A.
- Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM